Please use this identifier to cite or link to this item:
|Title:||p21-activated kinases and gastrointestinal cancer.||Austin Authors:||He, Hong ;Baldwin, Graham S||Affiliation:||Department of Surgery, University of Melbourne, Austin Health, Heidelberg, Victoria, Australia||Issue Date:||22-Oct-2012||Publication information:||Biochimica Et Biophysica Acta 2012; 1833(1): 33-9||Abstract:||p21-activated kinases (PAKs) were initially identified as effector proteins downstream from GTPases of the Rho family. To date, six members of the PAK family have been discovered in mammalian cells. PAKs play important roles in growth factor signalling, cytoskeletal remodelling, gene transcription, cell proliferation and oncogenic transformation. A large body of research has demonstrated that PAKs are up-regulated in several human cancers, and that their overexpression is linked to tumour progression and resistance to therapy. Structural and biochemical studies have revealed the mechanisms involved in PAK signalling, and opened the way to the development of PAK-targeted therapies for cancer treatment. Here we summarise recent findings from biological and clinical research on the role of PAKs in gastrointestinal cancer, and discuss the current status of PAK-targeted anticancer therapies.||Gov't Doc #:||23092728||URI:||http://ahro.austin.org.au/austinjspui/handle/1/11591||DOI:||10.1016/j.bbamcr.2012.10.015||URL:||https://pubmed.ncbi.nlm.nih.gov/23092728||Type:||Journal Article||Subjects:||Animals
Molecular Targeted Therapy.methods.trends
|Appears in Collections:||Journal articles|
Show full item record
checked on Nov 29, 2022
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.